Combo immunotherapy doubles response rates and may herald a new standard of care
Results from a recent phase II study published in the [...]
A test to gauge recurrence risk for kidney cancer is unable to predict which patients will benefit from adjuvant therapy
An American company called Genomic Health has been collaborating with [...]
Cancer Drugs Fund driving early access to promising new treatments
The National Institute for Health and Care Excellence (NICE) has [...]
Chi-Med and AstraZeneca initiate global phase III clinical trial of savolitinib in papillary kidney cancer (SAVOIR)
Chi-Med (Hutchinson Pharma), a Hong Kong-based biotechnology company, and AstraZeneca [...]
Biomarkers for personalised cancer treatment
This article reviews all the biomarkers that have been discovered [...]
Cancer vaccine ilixadencel triggers strong immune response in newly diagnosed kidney cancer tumours
Results from the first phase of a phase 1/2 clinical [...]
Tivozanib given the green light by European regulators for first-line treatment of advanced kidney cancer
Tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine [...]
New treatment options for papillary renal cell carcinoma
This video interview summarises treatments in development for papillary renal [...]
Cabozantinib significantly improves progression free survival compared to sunitinib as first-line treatment for advanced kidney cancer
Review by a blinded independent radiology review committee (IRC) has [...]
Tivozanib plus nivolumab combination enters phase II clinical trials
The phase I dose-escalation phase of the TiNivo trial, which [...]
